1
Return

Multifactorial Alterations in Lacosamide Exposure in an Elderly Woman with Symptomatic Epilepsy and Tuberculous Pleurisy: A Case Report

delete2025-10-01
delete0
delete
OA
AI
R
Ryo Takeda
S
Shohei Matsuda
T
Tomoharu Yokooji
K
Keisuke Oda
H
Hideki Takakura
N
Nobuhiro Mori
T
Teruo Murakami
K
Kei Omoda *
DOI:10.1248/bpb.b25-00199delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
An elderly woman taking lacosamide (LCM) for epilepsy was diagnosed with tuberculous pleurisy. In the hospital, she received a four-drug combination therapy with rifampicin (RFP), isoniazid, pyrazinamide, and ethambutol for tuberculous pleurisy, in addition to medications for symptomatic epilepsy. At admission, her renal function was mildly impaired but remained stable throughout hospitalization. Serum albumin levels were slightly below the normal range. C-reactive protein was markedly elevated on day 4 but returned to normal by the time of discharge. On day 4, therapeutic drug monitoring (TDM) was initiated for LCM, a substrate for CYP2C19 and P-glycoprotein, because RFP can induce multiple cytochrome P450s (CYPs) and P-glycoprotein. Initially, the doses of RFP and LCM were 450and 100mg/d, respectively, and the serum concentration of LCM was 9.5 mu g/mL (day 4). On day 12, the serum concentration of LCM decreased to 4.1 mu g/mL, and the dose of LCM was increased to 200mg/d. The dose of LCM was further increased to 300mg/d on day 60 to maintain the serum concentration of LCM at approximately 10 mu g/mL. The estimated serum concentration (C) of LCM normalized by the dose (D) ratio, or C/D ratio, was 0.095 on day 4 and decreased to 0.03-0.04 after day 12. The LCM concentration during RFP co-administration may have been affected by the combined effects of RFP-mediated CYP2C19 and P-glycoprotein induction, the patient's inflammatory status, and concomitant anti-tuberculosis drugs. TDM is necessary to attain clinically effective serum concentrations of LCM when RFP is used concomitantly.
Keywords:
lacosamide
rifampicin
metabolic interaction
therapeutic drug monitoring
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

B
Biological and Pharmaceutical Bulletin
IF:
1.7
Papers:
23
Citations:
1.1W

Organization

H
Hiroshima International University
Scholars:
50
Papers: 25
Citations: 223
H
Hiroshima University
Scholars:
2.1W
Papers: 1.5W
Citations: 1.3W
Cited Papers

Cited Papers

Citing Papers

Citing Papers